Search Results

search
cgoncology_cover.jpg
CG Oncology to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
August 30, 2024 08:00 ET | CG Oncology Inc.
CG Oncology to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
cgoncology_cover.jpg
CG Oncology Announces Nature Medicine Publication of Final Results from CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive NMIBC
June 06, 2024 12:14 ET | CG Oncology Inc.
CG Oncology Announces Nature Medicine Publication of Final Results from CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab
cgoncology_cover.jpg
Cretostimogene Monotherapy Demonstrated 75.2% Complete Response Rate in High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
May 03, 2024 11:23 ET | CG Oncology Inc.
Cretostimogene Monotherapy Demonstrated 75.2% Complete Response Rate in High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
cgoncology_cover.jpg
CG Oncology to Host Virtual Investor Event on Friday, May 3, 2024
April 26, 2024 08:00 ET | CG Oncology Inc.
CG Oncology to Host Virtual Investor Event on Friday, May 3, 2024
cgoncology_cover.jpg
CG Oncology to Unveil Encouraging Results on Cretostimogene in Combination with Pembrolizumab at ASCO 2024
April 24, 2024 10:00 ET | CG Oncology Inc.
CG Oncology to Unveil Encouraging Results on Cretostimogene in Combination with Pembrolizumab at ASCO 2024
TIP_link_300x300.jpg
Cell and Gene Therapy Manufacturing Services Market worth $26.72 Billion, Globally, by 2030 – Comprehensive Study by The Insight Partners
September 27, 2023 10:12 ET | The Insight Partners
Pune, India, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Cell & gene therapy (CGT) programs are rapidly advancing from research & development to clinical trials and commercial approval. Establishing...
Figure 1
Theralase® Releases FY2022 Audited Financial Statements
April 26, 2023 18:01 ET | Theralase Technologies Inc.
TORONTO, April 26, 2023 (GLOBE NEWSWIRE) -- Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research...
theralase_logo_destroying_cancer.png
Theralase® Phase Ib NMIBC Clinical Study Published
June 21, 2022 07:00 ET | Theralase Technologies Inc.
TORONTO, June 21, 2022 (GLOBE NEWSWIRE) -- Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research...
Moderated by Benjamin Rehberg, Managing Director & Senior Partner at BCG
CAST Founder to Speak at BCG-led Virtual Software Intelligence Forum 2022
January 10, 2022 10:07 ET | CAST Software Inc.
NEW YORK and PARIS, Jan. 10, 2022 (GLOBE NEWSWIRE) -- CAST Founder & CEO, Vincent Delaroche, will be joining Benjamin Rehberg, BCG Senior Partner & Head of Technology Practice NA, as he...
theralase_logo_destroying_cancer.png
Theralase Releases 3Q21 Financial Statements and Newsletter
November 29, 2021 18:00 ET | Theralase Technologies Inc.
TORONTO, Nov. 29, 2021 (GLOBE NEWSWIRE) -- Theralase® Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research...